Abstract
In Reply.— We thank Drs Diamond, Freitag, and Feldman for their comments regarding our article. We share their concerns about the overzealous use of prochlorperazine (eg, prescribed at higher doses or as long-term prophylaxis) without further investigation. The incidence of extrapyramidal symptoms in patients who take prochlorperazine has been reported as 0.5% (5/1001).1 No reactions occurred in patients receiving less than 10 mg of prochlorperazine. 1 As described in our article, extrapyramidal symptoms can be minimized further by avoiding the use of prochlorperazine in susceptible individuals (eg, children). The most feared complication of antipsychotic drug therapy is tardive dyskinesia. However, this disorder is more common in the elderly and more likely to occur with exposure to high doses and during prolonged treatment. 2,3 Our collective experience during the past 8 years has shown intravenous prochlorperazine to be extremely safe as well as efficacious for the short-term treatment of acute headache
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
